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Introduction 
Specialty board certification was first instituted 
over 100 years ago. Driven by a need to protect 
the public from unqualified practitioners, the 
boards sought to standardize expectations of 
training, experience, and ethical behavior [1]. 
Although this initial goal of standardizing quality 
care has not changed, the certification processes 
have evolved significantly over time. The 
certification processes have also become 
monetized, leading to the accumulation of assets 
on medical board balance sheets (Figure 1). 
In 2014, the American Board of Internal Medicine 
(ABIM) changed the maintenance of certification 
(MOC) program, which in addition to a decennial 
exam would require physicians to complete 
interim tasks [2]. These changes were established 
in the name of protecting patients and ensuring 
that clinicians remain attuned to an accelerating 
landscape of medical advancements. However, 
the ABIM president, writing in reference to the 
MOC program, stated that the “ABIM did not 
engage the medical community in those changes 
[3].” In response to physician dissatisfaction, in 
2017 the ABIM created an alternative path by 
phasing in a biannual “Knowledge Check-In.” 
Other boards also made amendments, such as the 
American Board of Anesthesiology’s (ABA) weekly 
“MOCA Minute” in place of the decennial exam, or 
the American Board of Ophthalmology’s (ABO’s) 
“Quarterly Questions.” 
The Vision Initiative Commission (VIC), a group 
formed by the American Board of Medical 
Specialties (ABMS) as an independent committee 
to offer recommendations for change, released its 
Abstract 
Medical board organizations have accumulated 
large asset balances, in part due to the 
monetization of physician board recertification, as 
well as capital gains in positive investment 
conditions. Physicians across the country have 
raised concerns regarding the effectiveness and 
efficiency of existing recertification processes, to 
which the American Board of Medical Specialties 
and independent accreditation boards have 
responded with newly instituted changes. The 
present article analyzes the publicly available F990 
tax forms of the medical boards in an effort to 
provide data to the ongoing debate. Although 
some boards have begun to mobilize assets in 
recent years, many continue to accumulate wealth. 
It remains to be seen whether the new 
recertification programs will bring about change 
or perpetuate organizational wealth. 
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final report in February 2019 [4]. The VIC 
emphasized that recertification must remain 
distinct in its objectives from the initial 
certification, in that continuing certification must 
focus on diplomats staying up to date on medical 
advances rather than reaffirming their full body of 
knowledge. This recommendation set the stage 
for a transition from summative to formative 
interval assessments, analogous to the changes 
made by the ABA, ABO, and ABIM. The ABMS has 
since introduced CertLink, a web-based 
longitudinal assessment platform that adapts to 
user feedback on relevance and performance. The 
platform is being introduced by seven boards. It 
serves as a sign of positive change and 
responsiveness to physician feedback. 
  
 
Figure 1. Histogram of net asset balances among medical boards and accreditation councils. 
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Concerns have been raised among physicians 
regarding the validity of MOC translating into 
improved patient care, the increasing non-clinical 
time requirements, and mistrust of the medical 
boards [5]. The notion of alternative financial 
motives among the specialty boards has become 
a flashpoint. In 2015, public financial data from 
the medical boards was compiled by two of the 
present authors to increase transparency in this 
dialogue. The data led to the conclusion that the 
development of the MOC program furthered the 
monetization of the recertification process [6]. 
This study is an update to the original article that 
aims to provide recent data for the continued 
dialogue. 
 
Methods and Data 
The IRS Form 990 (F990) is a required annual IRS 
filing for organizations exempt from income tax. 
In addition to financial information, it reports on 
the organization’s mission, governance, 
compliance with tax filing requirements, and 
compensation. The websites 
Projects.Propublica.org/nonprofits [7] and 
Guidestar.org [8] served as the primary resources 
for locating publicly available F990s of the 
accreditation boards. 
Dates of the included F990s range from 1997 to 
2018; all publicly available F990s for each board 
were included. To simplify data reporting, years 
used throughout the study correspond to the 
date listed on F990. Fiscal years vary from 
organization to organization; for example, a 2017 
F990 can reflect data as late June 2018 if the 
organization’s fiscal year begins in July. Member 
boards of the ABMS analyzed in the present study 
are the American Boards of Allergy and 
Immunology, Anesthesiology, Colon and Rectal 
Surgery, Dermatology, Emergency Medicine, 
Family Medicine, Internal Medicine (a fiscal 
subsidiary of the American Board of Internal 
Medicine Foundation), Medical Genetics and 
Genomics, Neurological Surgery, Nuclear 
Medicine, Obstetrics and Gynecology, 
Ophthalmology, Orthopaedic Surgery, Otolaryn-
gology - Head and Neck Surgery, Pathology, 
Pediatrics, Physical Medicine and Rehabilitation, 
Plastic Surgery, Preventive Medicine, Psychiatry 
and Neurology, Radiology, Surgery, Thoracic 
Surgery, and Urology. The analysis also includes 
independent boards deemed relevant to the 
study, including the American Boards of Clinical 
Neurophysiology, Facial Plastic and 
Reconstructive Surgery, Medical Physics, Oral and 
Maxillofacial Surgery, and Sleep Medicine. Data 
for ABIM Foundation and its fiscal subsidiary 
ABIM have been reported separately as well as 
combined. Data for the American Board of 
Hospice and Palliative Care has been excluded 
because this board was dissolved. We also report 
data for the Accreditation Council for Graduate 
Medical Education, the Accreditation Council for 
Continuing Medical Education, and the American 
Osteopathic Association. 
Limitations 
The present analysis aims to offer an objective 
financial snapshot of each accreditation board. 
The analysis is limited by the delay of public 
access to Form 990s, with most forms dating up 
to 2017 and a minority dating 2018. As previously 
noted, the dates in the study are the years listed 
on the Form 990, which reflect variable time 
frames depending on the individual 
organization’s fiscal year. The data has not been 
normalized relative to the sizes of the underlying 
membership (i.e. ABIM has a much larger 
constituency than the American Board of Clinical 
Neurophysiology). Prominent boards have larger 
positive balances, which generate greater 
compounding investment incomes, rendering 
comparisons between boards less valuable. 
Nonetheless, a substantial number of years for 
each board is included, offering sufficient data to 
trend and analyze. 
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Results 
The analysis is reported below in two 
components: 1) A figure with the latest net asset 
balance available for each accreditation board, 2) 
the compound annual growth rate (CAGR) over 
the timeframe of data available for each 
accreditation board, and 3) a tabulation with 
corresponding graph for each accreditation board 
exhibiting trends of total annual revenues, 
expenses, net gain/losses (i.e. total revenues 
minus total expenses), and end of year net assets 
(i.e. assets minus liabilities). The figures and tables 
that make up this third component of the analysis 
can be found in the supplemental Data Tables 
section. 
Figure 1 depicts the most recently available net 
asset balances (i.e. assets minus liabilities) of the 
analyzed organizations (ABIM and ABIM 
Foundation balances are aggregated). Among the 
organizations analyzed (Figure 1A, B), net assets 
of $85 million represent the 95th percentile, $37 
million the 75th percentile, $12 million the 50th 
percentile, and $5 million the 25th percentile. The 
combined net asset balances of the ABMS and its 
24 member boards totals $664 million, based on 
their most recent publicly available F990s. Among 
the boards, the three highest net asset balances 
were the American Board of Psychiatry and 
Neurology ($120.7m), American Board of Family 
Medicine ($92.7m), American Board of Pediatrics 
($80.3m), (Figure1). 
One metric for measuring the financial growth of 
organizations is the compound annual growth 
rate (CAGR), or the compounded rate of return 
required to grow an initial balance to an end 
balance. However, the metric assumes a linear 
trajectory, whereas the incomes of the boards 
have been growing at an accelerated pace in 
recent years in part due to compounding 
investment incomes. Nonetheless, the CAGRs 
reveal a telling picture of the financial growth 
among the boards. Table 1 is a table of the net 
asset balances of the earliest and latest publicly 
available F990s, as well as each organization’s 
corresponding CAGR over that timeframe. Among 
the organizations analyzed (Table 1), CAGRs of 
17% represent the 95th percentile, 11% the 75th 
percentile, 7% the 50th percentile, and 5% the 25th 
percentile (Table 1). 
 
Discussion 
The authors’ 2015 article, for which the present 
study serves as an update, concluded that the 
development of the MOC program has furthered 
the monetization of the recertification process [6]. 
Whether or not the MOC itself most effectively 
serves its mission of “collective professional self-
regulation in service to the public [1]” or improved 
quality of care may be a matter of debate. 
However, the present analysis does not aim to 
address these points, but rather to offer a data-
driven snapshot of the financial changes among 
the accreditation boards and councils in recent 
years. 
The combined net asset balances (i.e. assets minus 
liabilities) of the ABMS and its 24 member boards 
total $664 million, or $829 million if one includes 
non-ABMS boards and accreditation councils. 
Among the boards, the three highest net asset 
balances were the American Board of Psychiatry 
and Neurology ($120.7m), American Board of 
Family Medicine ($92.7m), and American Board of 
Pediatrics ($80.3m). As net gains continue to 
accumulate, net assets of many boards exhibit 
compound annual growth rates well above the 
SP500 CAGR over the available time horizons 
(6.3% to 9.1%). 
Although some boards have reduced their net 
assets in recent years despite favorable 
investment conditions, many continue to 
accumulate wealth. One argument for this 
monetary growth that has been raised by the 
boards is the need for reinvestment to develop  
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innovative modalities for the certification process. 
Although the data shows increase in both revenue 
and expenses, the rate of increase in net assets 
substantially outpaces both. This may change for 
the boards that are introducing CertLink, the web-
based longitudinal assessment program 
spearheaded by the ABMS. It serves as a positive 
example of the ABMS responding to the need for 
change, despite posing a significant expense to 
the individual boards. Implementation of CertLink 
is an opportunity for the boards to deploy their 
already accumulated wealth, thereby passing on 
the savings to diplomats. Whether this will be the 
case or costs will instead be passed on to 
diplomats remains to be seen. An argument can 
be made that the vast accumulating wealth should 
be deployed toward initiatives that benefit 
diplomats and the public within each board’s field, 
such as addressing physician burn out and patient 
access to care. 
Other arguments for retaining such large coffers 
have included the need to maintain financial 
solvency in case of unforeseen risks. Although 
solvency is a legitimate concern for any 
organization, it is difficult to justify the need for 
some of the accreditation boards and councils to 
retain net assets that are many multiples of annual 
expenses. One board reported net assets in excess 
of 8 times annual expenses, whereas another 
reported a multiple of 4 times annual expenses. 
The average multiple of net assets to annual 
expenses is 3.26 across the organizations 
analyzed (median 2.42). Compare this to large 
banks, which have high liquidity ratio 
requirements such as Morgan Stanley’s 2018 ratio 
of net tangible assets to operating expenses of 
2.38, or JP Morgan Chase’s ratio of 2.88 [9]. In the 
non-profit healthcare sector, compare the ratios  
to the American Heart Association, which in its 
2017 F990 has a ratio of 1.15; Medicins Sans 
Frontieres USA (Doctors Without Borders)’s 2017 
ratio of 0.62, or the American National Red Cross’s 
2017 ratio of 0.5 [7-8]. The disparity between the 
ratios of these organizations and the medical 
boards are concerning. 
It is important to reiterate the continued 
widespread discontent expressed by physicians 
with the MOC process. Cook et al. conducted a 
cross-specialty survey in 2016, which showed that 
only 24% of physicians feel MOC activities are 
relevant to their patients, 15% felt that it is worth 
their time and effort, and 81% believed it is a 
burden [10]. These findings were echoed in 
surveys of rheumatologists [11] and 
neurosurgeons [12]. Among the 515 
rheumatologists responding to Sawalha’s survey, 
43% believed that the primary reason for creating 
the MOC was the financial well-being of the 
boards themselves. This sentiment signals the 
need for restructuring. 
 
Conclusion 
Overall, there are promising signs of changes to 
the MOC process as evidenced by the VIC’s final 
report, the new CertLink assessment platform, and 
other programs introduced by the ABA, ABO, and 
ABIM. However, many, but not all, boards and 
councils continue to accumulate substantial 
assets, a finding that does little to alleviate the 
concerns of physicians who are dissatisfied with 
the MOC process and mistrust the organizations’ 
motives. 
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Table 1. Compound annual growth rates (CAGRs) and earliest/latest available net asset balances. 
Accreditation Board / Council CAGR 
Start 
Year 
End 
Year 
Start Net 
Asset Balance 
End Net Asset 
Balance 
American Board of Preventive Medicine 18% 2004 2017 $861,755 $7,432,337 
American Board of Otolaryngology 17% 2004 2017 $1,865,357 $13,972,942 
American Board of Psychiatry and Neurology 17% 2004 2017 $16,508,407 $120,727,606 
American Board of Facial Plastic and Reconstructive 
Surgery 
16% 2005 2017 $149,576 $888,886 
American Board of Dermatology 15% 2004 2017 $2,215,061 $12,964,072 
American Board of Family Medicine 14% 2004 2016 $18,817,732 $92,700,936 
American Board of Pathology 14% 2004 2017 $3,415,957 $18,272,602 
American Board of Urology 12% 2005 2018 $2,365,391 $10,802,518 
American Board of Plastic Surgery 11% 2004 2017 $1,888,823 $6,956,053 
American Board of Oral and Maxillofacial Surgery 11% 1997 2017 $1,142,250 $8,425,082 
American Board of Radiology 9% 2004 2017 $12,906,311 $40,852,834 
American Board of Emergency Medicine 9% 2004 2017 $12,049,484 $37,411,222 
American Board of Physical Medicine and 
Rehabilitation 
9% 2004 2017 $4,536,269 $13,969,758 
American Board of Obstetrics and Gynecology 9% 2004 2017 $17,397,346 $52,912,825 
American Board of Ophthalmology 9% 2004 2017 $1,904,639 $5,517,243 
Accreditation Council for Graduate Medical Education 8% 1998 2017 $10,572,089 $48,716,153 
American Board of Medical Genetics and Genomics 7% 2004 2017 $901,209 $2,052,846 
American Board of Orthopaedic Surgery 6% 2004 2017 $18,223,969 $39,939,947 
American Board of Colon and Rectal Surgery 6% 2004 2018 $487,856 $1,111,654 
American Board of Anesthesiology 5% 1998 2017 $11,829,063 $32,602,547 
Accreditation Council for Continuing Medical 
Education 
5% 2004 2017 $3,153,392 $6,252,301 
American Board of Nuclear Medicine 5% 1998 2017 $1,303,901 $3,380,582 
American Board of Neurological Surgery 5% 2001 2017 $1,713,866 $3,796,315 
American Board of Medical Specialties 5% 2004 2017 $8,582,219 $15,490,966 
American Board of Allergy and Immunology 5% 2006 2017 $3,240,858 $5,319,145 
American Board of Thoracic Surgery 4% 2005 2017 $9,298,010 $15,158,594 
American Board of Pediatrics 4% 2003 2016 $49,567,584 $80,331,587 
American Board of Medical Physics 3% 2004 2018 $136,601 $215,016 
American Osteopathic Association 3% 1997 2017 $27,085,742 $50,103,097 
American Board of Internal Medicine Foundation 2% 1997 2017 $46,247,684 $71,353,299 
American Board of Clinical Neurophysiology -5% 1998 2017 $56,023 $21,452 
American Board of Surgery -6% 2004 2017 $19,017,633 $8,960,482 
American Board of Sleep Medicine -9% 2004 2017 $1,616,785 $452,091 
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Supplemental Data: Individual Board/Accreditation Council Data Tables  
American Board of Medical Specialties 
Relative to the earliest available F990 from 2004, ABMS’s 2017 filing shows a 5-fold increase in annual revenues and 
expenses, and a 1.81-fold increase in net assets to $15.4 million.  
 
American 
Board of 
Medical 
Specialties 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
3.605 4.252 4.430 5.061 5.484 7.497 9.632 13.311 15.519 18.607 18.559 18.217 18.165 19.644 
Expense  
($ million) 
3.517 3.795 3.922 5.670 5.378 6.006 9.794 11.761 14.866 16.797 18.496 17.928 18.574 20.754 
Net 
Gain/Loss  
($ million) 
0.088 0.457 0.507 (0.608) 0.106 1.491 (0.162) 1.550 0.653 1.811 0.063 0.289 (0.409) (1.111) 
End of year 
net asset 
balance  
($ million) 
8.582 9.002 9.797 9.402 8.025 10.151 10.587 11.906 13.192 16.460 16.743 16.676 16.267 15.491 
 
 
American Board of Allergy and Immunology 
Relative to the earliest available F990 from 2004, the American Board of Allergy and Immunology’s 2017 filing shows a 2-
fold increase in revenues and expenses, and a 1.64-fold increase in net assets to $5.3 million. 
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American Board of 
Allergy and 
Immunology 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 0.748 1.222 0.958 1.315 1.305 1.740 1.420 1.920 1.590 1.920 1.737 1.530 
Expense ($ million) 0.867 0.987 1.158 1.313 1.255 1.455 1.427 1.501 1.526 1.705 1.677 1.809 
Net Gain/Loss ($ million) (0.120) 0.236 (0.200) 0.002 0.050 0.285 (0.007) 0.419 0.063 0.215 0.061 (0.279) 
End of year net asset 
balance ($ million) 
3.241 3.478 2.649 2.960 3.278 3.618 3.850 4.693 5.059 5.185 5.293 5.319 
 
 
American Board of Anesthesiology 
Relative to the earliest available F990 from 1998, the American Board of Anesthesiology’s 2017 filing shows a 3.7-fold 
increase in revenues, a 4.39-fold increase in expenses, and a 2.76-fold increase in net assets to $32.6 million.  
 
American Board 
of Anesthesiology 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Revenue ($ million) 4.661 4.738 4.367 3.745 4.128 5.054 6.512 7.434 11.018 8.197 
Expense ($ million) 3.500 3.485 3.685 4.133 4.461 4.892 5.460 6.151 6.606 7.180 
Net Gain/Loss  
($ million) 
1.161 1.252 0.683 (0.388) (0.333) 0.162 1.052 1.284 4.412 1.017 
End of year net 
asset balance  
($ million) 
11.829 13.762 14.243 13.136 11.651 13.816 15.290 15.280 16.934 18.880 
 
American Board of 
Anesthesiology 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 6.824 9.474 12.397 10.843 13.027 17.032 15.842 13.602 15.730 17.059 
Expense ($ million) 8.206 9.833 10.149 9.581 10.673 13.390 13.936 14.012 14.368 15.372 
Net Gain/Loss  
($ million) 
(1.382) (0.359) 2.248 1.262 2.355 3.642 1.906 (0.410) 1.362 1.687 
End of year net 
asset balance  
($ million) 
12.570 15.322 17.331 17.651 21.382 25.381 27.183 25.681 28.431 32.603 
 
 
American Board of Clinical Neurophysiology 
Relative to the earliest available F990 from 1998, the American Board of Clinical Neurophysiology’s 2017 filing shows a 
decline in revenues, expenses and net asset balance.  
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American Board 
of Clinical 
Neurophysiology 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Revenue ($ million) 0.048 0.042 0.037 0.046 0.033 0.023 0.023 0.030 0.023 0.037 0.028 
Expense ($ million) 0.049 0.045 0.047 0.040 0.041 0.032 0.030 0.037 0.034 0.031 0.036 
Net Gain/Loss  
($ million) 
(0.001) (0.003) (0.010) 0.006 (0.008) (0.009) (0.006) (0.007) (0.012) 0.007 (0.009) 
End of year net 
asset balance  
($ million) 
0.056 0.053 0.043 0.049 0.040 0.031 0.025 0.019 0.007 0.014 0.005 
 
American Board of 
Clinical 
Neurophysiology 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 0.021 0.059 0.050 0.036 0.062 0.040 0.041 0.073 0.020 
Expense ($ million) 0.031 0.028 0.050 0.031 0.060 0.048 0.045 0.053 0.038 
Net Gain/Loss  
($ million) 
(0.011) 0.032 0.001 0.005 0.001 (0.008) (0.005) 0.020 (0.019) 
End of year net asset 
balance ($ million) 
(0.006) 0.026 0.027 0.031 0.033 0.025 0.020 0.040 0.021 
 
 
American Board of Colon and Rectal Surgery 
Relative to the earliest available F990 from 2004, the American Board of Colon and Rectal Surgery’s 2018 filing shows a 
2.7-fold increase in revenues, a 2.1-fold increase in expenses, and a 2.28-fold increase in net assets to $1.1 million.  
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American Board 
of Colon and 
Rectal Surgery 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Revenue  
($ million) 
0.378 0.362 0.404 0.478 0.423 0.441 0.508 0.702 0.745 0.796 0.898 0.773 0.747 0.832 1.029 
Expense  
($ million) 
0.343 0.371 0.392 0.420 0.445 0.470 0.511 0.608 0.672 0.737 0.750 0.749 0.830 0.828 0.732 
Net Gain/Loss  
($ million) 
0.035 (0.010) 0.012 0.058 (0.021) (0.029) (0.003) 0.094 0.074 0.059 0.148 0.024 (0.083) 0.006 0.297 
End of year net 
asset balance  
($ million) 
0.488 0.478 0.490 0.548 0.527 0.498 0.495 0.589 0.663 0.722 0.869 0.893 0.810 0.815 1.112 
 
 
American Board of Dermatology 
Relative to the earliest available F990 from 2004, the American Board of Dermatology’s 2017 filing shows a 2.56-fold 
increase in revenues, a 2.59-fold increase in expenses, but a 5.85-fold increase in net assets to $12.9 million.  
 
American Board 
of Dermatology 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
1.321 1.646 1.616 1.589 2.531 1.373 2.027 2.698 2.754 2.723 2.621 2.390 3.219 3.374 
Expense  
($ million) 
1.078 1.205 1.363 1.294 1.311 1.560 1.502 1.498 1.572 1.980 2.345 2.307 2.432 2.792 
Net Gain/Loss  
($ million) 
0.243 0.441 0.253 0.295 1.219 (0.187) 0.525 1.200 1.182 0.743 0.276 0.082 0.787 0.581 
End of year net 
asset balance  
($ million) 
2.215 2.648 2.995 3.314 3.710 4.247 5.128 6.216 7.885 9.464 10.159 10.321 11.230 12.964 
 
 
American Board of Emergency Medicine 
Relative to the earliest available F990 from 2004, the American Board of Emergency Medicine’s 2017 filing shows a 2.37-
fold increase in revenues, a 2.34-fold increase in expenses, and a 3.1-fold increase in net assets to $37.4 million.  
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American Board 
of Emergency 
Medicine 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
7.137 7.511 8.866 9.408 9.529 10.321 11.607 14.497 13.246 14.940 15.757 14.371 16.117 16.902 
Expense  
($ million) 
6.603 6.627 7.606 7.884 8.516 9.472 9.330 10.185 10.404 11.640 13.683 14.496 14.766 15.464 
Net Gain/Loss  
($ million) 
0.533 0.885 1.260 1.525 1.013 0.849 2.278 4.311 2.842 3.300 2.074 (0.125) 1.350 1.438 
End of year net 
asset balance  
($ million) 
12.049 13.488 16.190 16.800 15.204 16.729 21.826 22.939 26.993 31.965 32.677 32.506 35.572 37.411 
 
 
American Board of Facial Plastic and Reconstructive Surgery 
Relative to the earliest available F990 from 2005, the American Board of Facial Plastic and Reconstructive Surgery’s 2017 
filing shows a 1.41-fold increase in revenues, a 1.76-fold increase in expenses, but a 5.94-fold increase in net assets to 
$889 thousand.  
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American Board of 
Facial Plastic and 
Reconstructive 
Surgery 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 0.464 0.587 0.509 0.537 0.555 0.520 0.611 0.555 0.611 0.640 0.708 0.693 0.656 
Expense ($ million) 0.379 0.484 0.393 0.427 0.447 0.468 0.573 0.499 0.618 0.596 0.613 0.657 0.667 
Net Gain/Loss  
($ million) 
0.085 0.103 0.116 0.111 0.107 0.053 0.037 0.056 (0.007) 0.044 0.095 0.036 (0.011) 
End of year net 
asset balance  
($ million) 
0.150 0.253 0.369 0.479 0.586 0.639 0.676 0.733 0.725 0.769 0.864 0.900 0.889 
 
 
American Board of Family Medicine 
Relative to the earliest available F990 from 2004, the American Board of Family Medicine’s 2016 filing shows a 1.89-fold 
increase in revenues, a 2.36-fold increase in expenses, but a 4.93-fold increase in net assets to $92.7 million. Net gains 
have been notably positive every year examined. 
 
 
American Board of 
Family Medicine 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Revenue ($ million) 16.794 15.144 17.195 21.712 23.140 24.185 23.617 22.409 28.880 31.837 36.276 34.362 31.808 
Expense ($ million) 11.940 12.498 14.118 18.326 15.210 17.220 18.991 19.594 24.137 28.017 28.373 27.948 28.175 
Net Gain/Loss  
($ million) 
4.855 2.645 3.078 3.387 7.930 6.965 4.626 2.815 4.743 3.819 7.903 6.414 3.633 
End of year net 
asset balance  
($ million) 
18.818 21.748 25.940 29.309 28.517 41.386 48.574 48.930 57.461 79.833 84.244 84.560 92.701 
 
 
American Board of Internal Medicine and the ABIM Foundation (Combined and Separate)  
The ABIM Foundation is the parent organization of the ABIM, so their aggregated performance provides a more complete 
picture of the ABIM’s financial status. However, figures and tables are offered for the combined and separate F990s. 
Relative to their earliest available F990s from 1997, the 2017 filings show a 2.87-fold increase in revenues, a 3.79-fold 
increase in expenses, but net assets ($21.4) are .47 of their original sum. The trends reveal increasing financial activity as 
reflected in the rise in revenues and expenses, however, the organization has decreased its retained net assets due to net 
losses in 7 of the 10 previous years. 
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American Board 
of Internal 
Medicine and 
the ABIM 
Foundation 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Revenue  
($ million) 
23.014 24.069 27.600 22.357 14.430 22.179 27.307 26.298 29.706 37.812 40.762 
Expense  
($ million) 
16.674 22.957 24.686 24.579 24.337 25.500 28.794 26.999 27.481 40.070 44.918 
Net Gain/Loss  
($ million) 
6.340 1.112 2.915 (2.222) (9.908) (3.321) (1.487) (0.701) 2.225 (2.258) (4.156) 
End of year net 
asset balance  
($ million) 
45.689 54.043 61.983 54.009 42.048 43.639 45.179 46.754 51.572 57.330 44.546 
 
American Board of 
Internal Medicine 
and the ABIM 
Foundation 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 36.785 44.915 48.918 51.709 78.251 61.178 66.368 59.283 62.896 65.938 
Expense ($ million) 45.714 51.325 52.963 54.536 58.506 62.932 66.818 67.032 61.882 63.171 
Net Gain/Loss  
($ million) 
(8.929) (6.410) (4.045) (2.827) 19.745 (1.754) (0.450) (7.749) 1.014 2.767 
End of year net 
asset balance  
($ million) 
21.111 20.109 27.345 23.478 30.691 31.523 26.612 13.626 19.211 21.409 
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American Board 
of Internal 
Medicine 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Revenue  
($ million) 
17.135 12.919 17.315 17.427 16.042 22.955 23.407 23.882 26.992 27.387 31.309 
Expense  
($ million) 
15.816 22.008 23.140 23.061 22.489 22.767 25.997 23.393 25.313 37.177 41.253 
Net Gain/Loss  
($ million) 
1.318 (9.090) (5.825) (5.634) (6.447) 0.188 (2.589) 0.489 1.679 (9.791) (9.944) 
End of year net 
asset balance  
($ million) 
(0.559) (5.576) (7.119) (8.571) (10.763) (10.930) (13.457) (13.186) (11.815) (21.504) (31.444) 
 
American Board 
of Internal 
Medicine 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 35.318 42.272 46.131 49.305 55.626 54.455 57.621 55.572 59.434 58.879 
Expense ($ million) 40.326 46.757 48.886 51.038 53.287 59.210 60.359 62.512 54.788 55.843 
Net Gain/Loss  
($ million) 
(5.009) (4.485) (2.755) (1.733) 2.339 (4.755) (2.738) (6.941) 4.646 3.036 
End of year net 
asset balance  
($ million) 
(36.476) (40.907) (43.661) (45.394) (43.150) (47.887) (50.643) (57.568) (52.939) (49.945) 
 
 
 
 
American Board 
of Internal 
Medicine 
Foundation 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Revenue  
($ million) 
5.880 11.150 10.285 4.929 (1.613) (0.776) 3.900 2.416 2.714 10.425 9.453 
Expense  
($ million) 
0.858 0.949 1.545 1.517 1.848 2.733 2.797 3.606 2.168 2.893 3.664 
Net Gain/Loss  
($ million) 
5.022 10.201 8.740 3.412 (3.461) (3.509) 1.102 (1.190) 0.546 7.532 5.788 
End of year net 
asset balance  
($ million) 
46.248 59.618 69.102 62.581 52.811 54.569 58.636 59.940 63.387 78.834 75.990 
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American Board 
of Internal 
Medicine 
Foundation 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 1.467 2.644 2.787 2.404 22.625 6.723 8.747 3.711 3.461 7.059 
Expense ($ million) 5.387 4.568 4.077 3.498 5.219 3.722 6.459 4.519 7.093 7.328 
Net Gain/Loss  
($ million) 
(3.920) (1.925) (1.290) (1.094) 17.407 3.001 2.288 (0.808) (3.632) (0.269) 
End of year net 
asset balance  
($ million) 
57.587 61.016 71.007 68.872 73.842 79.409 77.255 71.195 72.150 71.353 
 
 
American Board of Medical Genetics and Genomics 
Relative to the earliest available F990 from 2004, the American Board of Medical Genetics and Genomics 2017 filing shows 
a 2.62-fold increase in revenues, a 4.91-fold increase in expenses, and a 2.28-fold increase in net assets to $2 million. 
 
American Board 
of Medical 
Genetics and 
Genomics 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
0.361 0.655 0.441 0.746 0.817 0.968 1.179 0.564 1.292 0.704 1.390 0.731 1.468 0.947 
Expense  
($ million) 
0.245 0.326 0.490 0.858 0.022 0.748 0.736 0.692 0.875 0.874 1.030 1.043 1.166 1.202 
Net Gain/Loss  
($ million) 
0.117 0.328 (0.049) (0.111) 0.795 0.219 0.442 (0.128) 0.417 (0.170) 0.361 (0.312) 0.302 (0.255) 
End of year net 
asset balance  
($ million) 
0.901 1.241 1.205 1.096 1.022 1.306 1.775 1.627 2.078 1.944 2.278 1.918 2.237 2.053 
 
 
American Board of Nuclear Medicine 
Relative to the earliest available F990 from 1998, the American Board of Nuclear Medicine’s 2017 filing shows a 1.87-fold 
increase in revenues, a 2.95-fold increase in expenses, and a 2.59-fold increase in net assets to $3.38 million.  
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American Board 
of Nuclear 
Medicine 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Revenue ($ million) 0.430 0.428 0.456 0.331 0.413 0.411 0.469 0.400 0.544 0.743 
Expense ($ million) 0.278 0.283 0.330 0.360 0.369 0.436 0.385 0.360 0.585 0.604 
Net Gain/Loss  
($ million) 
0.151 0.145 0.126 (0.030) 0.044 (0.026) 0.084 0.040 (0.041) 0.140 
End of year net 
asset balance  
($ million) 
1.304 1.449 1.575 1.546 1.586 2.394 1.154 2.093 1.988 2.275 
 
American Board 
of Nuclear 
Medicine 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 0.256 0.769 0.814 0.786 1.104 1.142 0.956 1.099 1.006 0.803 
Expense ($ million) 0.651 0.682 0.664 0.731 0.756 0.788 0.881 0.925 0.924 0.821 
Net Gain/Loss  
($ million) 
(0.394) 0.087 0.150 0.055 0.348 0.354 0.075 0.174 0.082 (0.018) 
End of year net 
asset balance  
($ million) 
1.880 1.967 2.230 2.163 2.545 2.998 3.102 3.059 3.249 3.381 
 
 
American Board of Obstetrics and Gynecology 
Relative to the earliest available F990 from 2004, the American Board of Obstetrics and Gynecology’s 2017 filing shows a 
1.99-fold increase in revenues, a 2.47-fold increase in expenses, and a 3.04-fold increase in net assets to $52.9 million.  
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American Board 
of Obstetrics and 
Gynecology 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
8.674 9.957 11.870 11.486 5.170 12.792 14.279 13.416 14.920 17.697 15.610 17.793 16.797 17.231 
Expense  
($ million) 
7.185 7.707 8.023 9.328 10.113 10.403 10.826 11.395 11.154 15.470 16.552 14.196 15.012 17.739 
Net Gain/Loss  
($ million) 
1.489 2.250 3.846 2.158 (4.942) 2.389 3.453 2.021 3.766 2.227 (0.842) 3.597 1.785 (0.507) 
End of year net 
asset balance  
($ million) 
17.397 18.600 22.446 24.605 19.662 25.170 30.820 31.838 37.491 44.053 44.218 45.477 49.814 52.913 
 
 
American Board of Ophthalmology 
Relative to the earliest available F990 from 2004, the American Board of Ophthalmology’s 2017 filing shows a 1.90-fold 
increase in revenues, a 2.08-fold increase in expenses, and a 2.9-fold increase in net assets. Net asset balance reached a 
peak of $6.9 million in 2014 and has since pullback slightly to $5.5 million. 
 
American Board 
of 
Ophthalmology 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
2.447 3.493 2.769 3.482 2.977 3.487 3.030 4.130 4.750 5.166 5.262 4.653 4.537 4.657 
Expense  
($ million) 
2.282 2.613 2.549 2.618 2.766 3.057 3.293 3.471 3.964 4.786 4.904 4.946 5.812 4.757 
Net Gain/Loss  
($ million) 
0.166 0.880 0.219 0.864 0.211 0.431 (0.263) 0.659 0.787 0.380 0.357 (0.293) (1.275) (0.100) 
End of year net 
asset balance  
($ million) 
1.905 2.773 3.220 4.068 3.400 4.298 4.686 5.116 6.083 6.739 6.977 6.375 5.371 5.517 
 
American Board of Oral and Maxillofacial Surgery 
Relative to the earliest available F990 from 1997, the American Board of Ophthalmology’s 2017 filing shows a 5.21-fold 
increase in revenues, a 4.14-fold increase in expenses, but a 7.38-fold increase in net assets to $8.4 million. 
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American Board of 
Oral and 
Maxillofacial 
Surgery 1997 1998 2001 2002 2004 2005 2006 2007 2008 2009 2010 2011 
Revenue ($ million) 0.803 1.020 1.239 1.443 1.650 1.761 1.865 2.160 1.781 1.904 2.405 2.831 
Expense ($ million) 0.839 0.865 1.082 1.292 1.398 1.524 1.574 1.726 1.890 2.121 2.376 2.258 
Net Gain/Loss  
($ million) 
(0.036) 0.155 0.157 0.151 0.251 0.236 0.290 0.433 (0.110) (0.217) 0.029 0.573 
End of year net asset 
balance ($ million) 
1.142 1.323 1.348 1.544 1.924 2.185 2.611 2.935 1.816 2.492 2.562 2.970 
 
American Board of Oral and 
Maxillofacial Surgery 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 2.974 3.485 4.010 3.995 4.121 4.181 
Expense ($ million) 2.759 2.926 2.685 2.781 3.140 3.474 
Net Gain/Loss ($ million) 0.215 0.559 1.325 1.214 0.981 0.707 
End of year net asset balance  
($ million) 
3.342 3.919 5.280 6.208 7.416 8.425 
 
 
American Board of Orthopedic Surgery 
Relative to the earliest available F990 from 2004, the American Board of Orthopaedic Surgery’s 2017 filing shows a 2.28-
fold increase in revenues, a 2.52-fold increase in expenses, and a 2.19-fold increase in net assets to $39.9 million.  
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American Board 
of Orthopedic 
Surgery 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
4.736 5.109 5.610 5.630 4.778 5.984 8.513 7.852 7.528 8.214 8.257 8.337 8.241 10.787 
Expense  
($ million) 
3.487 4.175 4.543 5.004 4.971 5.276 6.029 6.515 6.727 7.141 7.198 7.640 8.035 8.772 
Net Gain/Loss  
($ million) 
1.248 0.934 1.068 0.626 (0.193) 0.708 2.484 1.337 0.801 1.073 1.060 0.698 0.206 2.015 
End of year net 
asset balance  
($ million) 
18.224 19.785 21.929 21.035 19.081 20.731 23.325 25.257 27.148 31.526 31.406 34.062 36.638 39.940 
 
 
American Board of Otolaryngology 
Relative to the earliest available F990 from 2004, the American Board of Otolaryngology’s 2017 filing shows a 1.78-fold 
increase in revenues, a 2.42-fold increase in expenses, and a 7.49-fold increase in net assets to $13.97 million. 
 
American Board 
of 
Otolaryngology 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
2.181 2.183 2.287 2.662 2.388 2.526 2.621 3.969 3.262 3.713 4.216 4.100 3.973 3.888 
Expense  
($ million) 
1.588 1.624 1.565 1.547 1.800 1.890 2.163 2.611 2.838 3.123 3.063 3.005 3.515 3.848 
Net Gain/Loss  
($ million) 
0.593 0.559 0.721 1.115 0.589 0.636 0.458 1.358 0.424 0.590 1.153 1.095 0.459 0.040 
End of year net 
asset balance  
($ million) 
1.865 2.424 3.147 4.147 3.421 4.957 6.018 7.142 9.259 10.522 11.441 11.801 12.681 13.973 
 
 
American Board of Pathology 
Relative to the earliest available F990 from 2004, the American Board of Pathology’s 2017 filing shows a 1.55-fold increase 
in revenues, a 2.03-fold increase in expenses, and a 5.35-fold increase in net assets to $1.8 million.  
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American Board of 
Pathology 2004 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 2.939 3.188 3.627 1.782 3.642 3.270 3.577 3.874 5.681 4.949 4.387 4.516 4.553 
Expense ($ million) 2.169 2.299 2.340 2.430 2.425 2.519 2.717 3.194 3.275 3.481 3.780 4.031 4.409 
Net Gain/Loss  
($ million) 
0.770 0.890 1.287 (0.648) 1.217 0.751 0.860 0.680 2.406 1.469 0.607 0.485 0.144 
End of year net 
asset balance  
($ million) 
3.416 5.901 6.972 6.139 7.498 8.630 9.278 10.490 14.082 15.284 15.488 16.419 18.273 
 
 
American Board of Pediatrics 
Relative to the earliest available F990 from 2003, the American Board of Pediatrics 2016 filing shows a 2.66-fold increase in 
revenues, a 2.45-fold increase in expenses, and a 1.62-fold increase in net assets to $80 million. Net assets notably 
increased from 2015 to 2016 by $14.6 million. 
 
American Board 
of Pediatrics 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Revenue  
($ million) 
12.958 13.766 18.671 20.095 19.865 14.948 18.140 20.221 27.090 27.539 27.904 30.468 31.591 34.504 
Expense  
($ million) 
12.810 14.550 14.891 16.089 19.070 19.573 20.854 20.737 23.416 25.125 24.351 29.800 29.767 31.377 
Net Gain/Loss  
($ million) 
0.148 (0.784) 3.781 4.006 0.795 (4.625) (2.713) (0.516) 3.674 2.414 3.552 0.668 1.824 3.127 
End of year net 
asset balance  
($ million) 
49.568 51.141 57.677 61.545 41.337 41.796 43.573 43.516 46.163 62.780 68.173 64.392 65.736 80.332 
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American Board of Physical Medicine and Rehabilitation 
Relative to the earliest available F990 from 2004, the American Board of Physical Medicine and Rehabilitation 2017 filing 
shows a 2-fold increase in revenues, a 2.73-fold increase in expenses, and a 3.08-fold increase in net assets to $13.97 
million.  
 
American Board 
of Physical 
Medicine and 
Rehabilitation 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
2.622 2.632 2.704 3.273 3.017 3.516 3.926 4.174 4.853 5.658 3.886 4.584 4.730 5.246 
Expense  
($ million) 
1.759 1.933 2.006 2.235 2.483 2.844 3.094 3.263 3.670 3.974 4.200 4.093 4.162 4.809 
Net Gain/Loss  
($ million) 
0.864 0.699 0.698 1.038 0.535 0.671 0.833 0.911 1.183 1.684 (0.314) 0.491 0.568 0.437 
End of year net 
asset balance  
($ million) 
4.536 5.235 5.933 6.971 7.505 8.177 9.010 9.920 11.104 12.788 12.474 12.965 13.533 13.970 
 
 
American Board of Plastic Surgery 
Relative to the earliest available F990 from 2004, the American Board of Plastic Surgery and Rehabilitation 2017 filing 
shows a 1.79-fold increase in revenues, a 2.06-fold increase in expenses, and a 3.68-fold increase in net assets to $6.96 
million.  
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American Board 
of Plastic 
Surgery 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
1.714 1.797 2.071 2.470 2.213 2.424 2.467 2.568 3.120 2.835 2.997 3.159 3.115 3.070 
Expense  
($ million) 
1.407 1.601 1.631 1.903 1.998 2.270 2.511 2.652 2.829 2.391 2.578 2.511 2.531 2.897 
Net Gain/Loss  
($ million) 
0.306 0.196 0.440 0.567 0.215 0.154 (0.044) (0.084) 0.291 0.443 0.419 0.648 0.583 0.173 
End of year net 
asset balance  
($ million) 
1.889 2.085 2.512 3.091 2.841 3.289 3.429 3.136 3.332 4.128 4.696 5.141 5.991 6.956 
 
 
American Board of Preventive Medicine 
Relative to the earliest available F990 from 2004, the American Board of Preventive Medicine 2017 filing shows a 8.75-fold 
increase in revenues, a 5.08-fold increase in expenses, and a 8.62-fold increase in net assets to $7.4 million.  
 
American Board 
of Preventive 
Medicine 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
0.629 0.930 0.950 0.864 1.023 0.950 1.233 1.099 1.161 2.196 1.296 2.240 2.005 5.506 
Expense  
($ million) 
0.666 0.675 0.685 0.429 0.756 0.821 0.858 0.965 1.068 1.352 1.284 1.483 1.801 3.380 
Net Gain/Loss  
($ million) 
(0.036) 0.255 0.265 0.435 0.267 0.129 0.375 0.133 0.093 0.843 0.012 0.757 0.204 2.126 
End of year net 
asset balance  
($ million) 
0.862 1.159 1.490 1.877 1.779 2.205 2.630 2.694 2.916 3.989 3.990 4.514 4.990 7.432 
 
 
American Board of Psychiatry and Neurology 
Relative to the earliest available F990 from 2004, the American Board of Psychiatry and Neurology 2017 filing shows a 
1.68-fold increase in revenues, a 1.3-fold increase in expenses, and a 7.31-fold increase in net assets to $120.7 million, the 
highest among the boards. Whereas the organization’s revenues and expenses have stayed relatively stable, every year 
analyzed has shown significant net gains leading to the ballooning of net assets.  
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American Board 
of Psychiatry and 
Neurology 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
13.632 16.905 18.194 20.887 15.451 13.497 15.816 19.157 17.123 22.777 19.840 22.061 22.299 22.952 
Expense  
($ million) 
10.788 10.492 10.749 11.785 12.121 12.820 12.225 12.842 12.390 12.162 12.124 12.335 12.519 14.070 
Net Gain/Loss  
($ million) 
2.845 6.414 7.445 9.102 3.330 0.678 3.592 6.315 4.733 10.615 7.716 9.726 9.780 8.882 
End of year net 
asset balance  
($ million) 
16.508 23.134 30.355 38.993 32.731 39.201 46.443 50.389 58.246 74.359 85.764 90.824 103.052 120.728 
 
 
American Board of Radiology 
Relative to the earliest available F990 from 2004, the American Board of Radiology 2017 filing shows a 2.76-fold increase 
in revenues, a 3.92-fold increase in expenses, and a 3.17-fold increase in net assets to $40.85 million.  
 
American Board 
of Radiology 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
6.324 7.116 9.675 11.141 12.467 12.386 12.539 12.781 13.589 14.089 15.778 16.261 16.920 17.430 
Expense  
($ million) 
4.201 4.813 6.899 7.282 9.042 10.140 11.215 13.062 14.812 14.934 13.882 13.758 15.591 16.468 
Net Gain/Loss  
($ million) 
2.122 2.304 2.777 3.859 3.425 2.246 1.324 (0.281) (1.223) (0.845) 1.896 2.502 1.329 0.962 
End of year net 
asset balance  
($ million) 
12.906 16.093 19.867 23.000 22.669 27.766 30.060 30.053 29.986 31.060 33.977 35.666 38.957 40.853 
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American Board of Sleep Medicine 
Relative to the earliest available F990 from 2004, the American Board of Sleep Medicine 2017 filing shows a decrease in 
revenues, expenses, and net assets, down from $1.6 million to $452 thousand. No data was available for F990s dated 2009 
and 2010. 
 
American Board of 
Sleep Medicine 2004 2005 2006 2007 2008 2011 2012 2013 2016 2017 
Revenue ($ million) 0.761 0.102 0.122 0.134 0.017 0.071 0.137 0.066 0.091 0.115 
Expense ($ million) 0.533 0.004 0.167 2.044 0.037 0.052 0.201 0.058 0.059 0.024 
Net Gain/Loss ($ million) 0.229 0.099 (0.045) (1.910) (0.020) 0.020 (0.065) 0.008 0.031 0.092 
End of year net asset 
balance ($ million) 
1.617 0.099 0.054 0.454 0.434 0.401 0.336 0.344 0.340 0.452 
 
 
American Board of Surgery 
Relative to the earliest available F990 from 2004, the American Board of Surgery 2017 filing shows a 1.82-fold increase in 
revenues, a 2.8-fold increase in expenses, but a decrease in net assets from $19 million in 2004 to $8.96 million in 2017.  
 
American Board 
of Surgery 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
5.859 6.290 7.557 7.475 4.637 7.843 8.048 8.452 8.344 10.406 9.780 9.893 10.860 10.680 
Expense  
($ million) 
4.204 4.885 6.524 5.868 7.897 10.129 9.726 10.483 8.930 8.855 10.168 10.791 12.064 11.778 
Net Gain/Loss  
($ million) 
1.655 1.405 1.034 1.607 (3.259) (2.287) (1.678) (2.031) (0.586) 1.551 (0.388) (0.898) (1.204) (1.098) 
End of year net 
asset balance  
($ million) 
19.018 21.025 22.569 22.343 16.539 12.823 12.051 9.297 8.786 11.306 7.458 5.876 5.436 8.960 
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American Board of Thoracic Surgery 
Relative to the earliest available F990 from 2005, the American Board of Thoracic Surgery 2017 filing shows a 1.52-fold 
increase in revenues, a 1.76-fold increase in expenses, and a 1.63-fold increase in net assets to $15.16 million.  
 
American Board of 
Thoracic Surgery 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 1.561 1.943 2.011 1.450 1.609 1.933 1.917 2.142 2.151 2.287 1.761 2.163 2.369 
Expense ($ million) 1.065 1.090 1.519 1.507 1.545 1.736 1.858 2.024 2.114 1.932 1.922 2.262 1.877 
Net Gain/Loss  
($ million) 
0.495 0.852 0.492 (0.056) 0.064 0.198 0.059 0.118 0.037 0.355 (0.161) (0.099) 0.492 
End of year net 
asset balance  
($ million) 
9.298 10.502 10.700 8.216 9.622 10.464 10.133 10.737 11.828 12.321 12.042 12.714 15.159 
 
 
American Board of Urology 
Relative to the earliest available F990 from 2005, the American Board of Urology 2018 filing shows a 2.41-fold increase in 
revenues, a 2.26-fold increase in expenses, and a 4.57-fold increase in net assets to $10.8 million
 
American Board 
of Urology 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 
Revenue  
($ million) 
1.425 1.449 1.601 2.129 2.946 2.957 2.598 2.876 3.210 3.111 3.271 3.361 3.436 3.440 
Expense  
($ million) 
1.543 1.416 1.497 1.656 1.686 1.812 1.933 2.046 2.198 2.364 2.640 2.882 3.502 3.489 
Net Gain/Loss  
($ million) 
(0.118) 0.033 0.104 0.473 1.260 1.146 0.665 0.830 1.011 0.747 0.631 0.479 (0.066) (0.050) 
End of year net 
asset balance  
($ million) 
2.365 2.413 2.536 2.643 3.909 4.986 5.650 6.777 8.335 9.504 9.916 10.778 11.477 10.803 
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Accreditation Council for Continuing Medical Education 
Relative to the earliest available F990 from 2004, the Accreditation Council for Continuing Medical Education 2017 filing 
shows a 1.83-fold increase in revenues, a 2.68-fold increase in expenses, and a 1.98-fold increase in net assets to $6.2 
million.  
 
Accreditation 
Council for 
Continuing 
Medical 
Education 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue  
($ million) 
3.390 3.482 3.511 3.645 3.853 6.286 4.050 4.705 4.694 5.102 5.767 5.916 5.811 6.197 
Expense  
($ million) 
2.527 2.722 2.955 3.560 4.559 4.705 4.522 4.730 4.781 4.642 5.030 5.303 5.579 6.770 
Net Gain/Loss  
($ million) 
0.862 0.761 0.556 0.084 (0.706) 1.581 (0.472) (0.025) (0.087) 0.460 0.737 0.613 0.233 (0.574) 
End of year net 
asset balance  
($ million) 
3.153 3.909 4.599 4.703 3.128 5.134 4.846 4.545 4.531 5.086 5.756 6.132 6.421 6.252 
 
 
Accreditation Council for Graduate Medical Education 
Relative to the earliest available F990 from 1998, the Accreditation Council for Graduate Medical Education 2017 filing 
shows a 5.02-fold increase in revenues, a 5.59-fold increase in expenses, and a 4.61-fold increase in net assets to $48.7 
million.  
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Accreditation Council 
for Graduate Medical 
Education 1998 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Revenue ($ million) 12.474 19.408 18.840 19.312 20.044 21.068 28.482 27.760 29.924 28.578 
Expense ($ million) 11.269 14.615 16.183 19.318 20.566 21.356 23.373 26.262 26.847 30.912 
Net Gain/Loss ($ million) 1.206 4.793 2.657 (0.006) (0.522) (0.288) 5.109 1.498 3.077 (2.334) 
End of year net asset 
balance ($ million) 
10.572 14.036 16.050 15.306 16.241 15.921 20.766 23.111 24.726 15.553 
 
Accreditation Council for 
Graduate Medical 
Education 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 33.624 38.018 38.621 43.681 46.526 56.395 62.901 59.547 62.581 
Expense ($ million) 33.746 35.150 37.546 41.500 44.947 52.348 56.753 62.331 62.942 
Net Gain/Loss ($ million) (0.122) 2.869 1.075 2.181 1.579 4.047 6.149 (2.784) (0.361) 
End of year net asset 
balance ($ million) 
20.002 25.026 25.304 30.059 36.800 38.131 38.556 46.322 48.716 
 
 
American Osteopathic Association 
Relative to the earliest available F990 from 1997, the American Osteopathic Association 2017 filing shows a 2.34-fold 
increase in revenues, a 2.81-fold increase in expenses, and a 1.85-fold increase in net assets to $50 million.  
 
American 
Osteopathic 
Association 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Revenue ($ million) 20.148 23.092 24.942 23.518 25.296 23.058 27.093 30.526 34.444 34.694 35.764 
Expense ($ million) 16.530 20.144 22.193 22.803 24.071 25.329 25.812 29.557 34.067 33.043 34.612 
Net Gain/Loss  
($ million) 
3.618 2.948 2.749 0.715 1.225 (2.271) 1.281 0.969 0.378 1.652 1.152 
End of year net asset 
balance ($ million) 
27.086 30.474 32.618 32.522 32.796 32.059 35.305 37.139 36.139 39.275 38.209 
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American Osteopathic 
Association 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 
Revenue ($ million) 31.383 34.321 37.520 40.025 42.249 44.376 46.881 50.205 47.412 47.204 
Expense ($ million) 33.719 32.322 35.597 40.003 42.671 42.531 42.327 48.058 48.410 46.504 
Net Gain/Loss ($ million) (2.336) 1.999 1.923 0.021 (0.422) 1.845 4.554 2.147 (0.998) 0.700 
End of year net asset 
balance ($ million) 
30.392 35.198 40.605 37.543 39.485 43.277 47.118 46.752 48.160 50.103 
 
